Merck Sharp Dohme Gains FTZ Okay for New Jersey Pharma Research
Published Date: 6/27/2025
Notice
Summary
Merck, Sharp & Dohme LLC got the green light to make pharmaceutical products for research and development at their Rahway, New Jersey facility inside Foreign-Trade Zone 49. This means they can produce these products with special trade benefits, helping them save money and speed up their work. The approval was finalized on June 20, 2025, with no extra reviews needed.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in